INDEX OF SUBJECTS FOR VOLUME 30

Acanthamoeba spp. infections, 10
Acholeplasma laidlawii
  DNA fingerprinting, 92
Adherence
  coagulase-negative staphylococci, 167
  oral streptococci, 267
  P. aeruginosa to respiratory epithelium, 285
  Salmonella strains to HEp-2 cells, 59
Agglutination immunoassays
  agglutination inhibition, 37
  latex agglutination, 37
Aggregation
  of salmonellae (serotype Sendai), 59
  salt-aggregation test, 59
AIDS (acquired immunodeficiency syndrome)
  protozoan infections in, 3
Alginic acid-like compound, 17
Amoebic infections, 10
Amphotericin B
  liposomal, 193
  in systemic candidiasis, 193
Antibiotic resistance
  gentamicin, and *S. aureus*, 51
  methicillin, and *S. aureus*, 51, 245
  novobiocin, and *S. saprophyticus*, 253
  typing scheme for staphylococci, 161
Antibiotics and other antimicrobial substances
  daptomycin, and gram-positive cocci, 45
  liposomal amphotericin B, 193
  ofloxacin (isomer DR-3355), 227
  penicillin, and tolerant oral streptococci, 267
  post-antibiotic effect, 267
  sensitivity of coagulase-negative staphylococci, 253
Antibodies
  against giardial surface antigens, 207
  against *M. tuberculosis*, 101
  against *Neisseria* spp., 23
  against *P. penneri*, 279
  liposomal, against *C. albicans*, 193
Antigens
  of *E. coli*, 295
  fimbrial, of *P. penneri*, 279
  lipopolysaccharide, of *Brucella* spp., 37
  M. tuberculosis, immunoabsorbent-purified, 101
  of *Neisseria* spp., cross-reactivity, 23
  S. typhimurium, cholera-toxin-related, 213
  surface, of *G. lamblia*, 207
  surface carbohydrate, of *P. cepacia*, 17
Antiserum
  against fimbrial antigens of *P. penneri*, 279
  against surface antigens of *G. lamblia*, 207
API-Staph system, 161, 253
Auxotyping, *N. gonorrhoeae*, 239

Babesia divergens, infections, 11
Bacteraemia, serotyping of *E. coli*, 295
Bacteriophage *see* Phage typing
Biotyping schemes
  coagulase-negative staphylococci, 161
  V. cholerae, 137
Bladder infections, in diabetic mice, 105
Blood films, *B. divergens* in, 12
BOOKS RECEIVED
  Clinical oral microbiology (by T. W. MacFarlane and L. P. Samaranayake), 159
  Septicaemia and endocarditis: clinical and microbiological aspects (edited by D. C. Shanson), 2
  Virus morphology (by C. R. Madely and Anne M. Field), 159
BRENDA (bacterial restriction-endonuclease digest-analysis), 89
Brucella spp.
  chemical mutagenesis, 143
  lipopolysaccharide antigens, 37
  monoclonal antibodies, 37
  vaccine, 37, 143

Calcium, and action of daptomycin, 45
Campylobacters
  C. jejuni, endotoxin, and colonisation, 199
  C. jejuni, and host iron metabolism, 199
  DNA fingerprinting, 96
Candida albicans
  effects of cyclosporin A, 183
  liposomal amphotericin B with specific antibody, 193
  systemic infection, 183, 193
Carbohydrate fermentation tests, 253
Cholera toxin-related-antigen of *S. typhimurium*, 213
Chromatography
  anion-exchange, 69
  bovine thyroglobulin affinity, 69
  gel, 119
  immunoabsorbent affinity, 101
  ion exchange, 119
Chromosomal DNA fingerprinting, 89
Clostridium difficile, toxin A, 69
Continuous ambulatory peritoneal dialysis (CAPD), 161, 167
Cryptosporidium spp. infections, 7
Culture conditions
  S. typhimurium, and cholera toxin-related-antigen, 213
Cyclophosphamide
  effects on polymorphonuclear leucocytes, 183
Cyclosporin A
  effects in systemic candidiasis, 183
Cystic fibrosis patients, 285
Cysts
  Acanthamoeba spp., 10
  G. lamblia, 10
  P. carinii, 4
  T. gondii, 5
  see also Oocysts

Cytotoxicity assays
in systemic candidiasis, 183
toxin A of *C. difficile*, 69
verotoxins of *E. coli*, 219

Daptomycin
effects on gram-positive cocci, 45
Diabetic patients
susceptibility to bladder infection, 105
Diarrhoea
Cryposporidium spp., 7
in immunocompromised patients, 7
Diethyl sulphate (DES), as a mutagen, 143
DNA
fingerprinting, 89
hybridisation, 51, 89
polymorphism, 89
reporter molecule, 90
restriction analysis, 51, 89
DR-3355, ofloxacin isomer, 227

Elastase, human leucocyte, 285
Electronmicroscopy
adherence of *P. aeruginosa*, 285
effects of daptomycin on gram-positive cocci, 45
effects of penicillin on oral streptococci, 267
fimbrial haemagglutinins of *Salmonella*, 59
haemagglutinins and fimbriae of *P. penneri*, 279
immunoelectronmicroscopy, 129, 279
intracellular destruction of *S. typhimurium*, 79
monoclonal antibodies against *Mobiluncus* spp., 129
scanning, 45, 267, 285
transmission, 59, 129, 267
Electrophoresis
in DNA fingerprinting techniques, 90
molecular characterisation of *S. aureus*, 51
pulse field, 90
reverse field, 51
see also PAGE; SDS-PAGE
ELISA
antibodies in giardiasis, 207
anti-*Brucella* antibodies, 37
antigenic cross-reactivity of *Neisseria* spp., 23
anti-verotoxin antibodies, 219
enterotoxins of *S. aureus*, 245
serodiagnosis of tuberculosis, 101
whole cell, 23
Elution, by salmonellae, 59
Encephalitis
amoebic, 10
toxoplasmic, 6
Encephalitozoon cuniculi infections, 9
Endotoxins, of *C. jejuni*, 199
Enterobacter cloacae
bladder infection in diabetic mice, 105
virulence factors, 105
Enterococcus faecalis, and daptomycin, 45
Enterocytozoon bieneusi infections, 9
Enterotoxins
of *S. aureus*, 245
toxin A of *C. difficile*, 69

Enzyme profiles
coagulase-negative staphylococci, 253
Epidemiology
coagulase-negative staphylococci, 161, 167
peritonitis in dialysis patients, 161, 167
S. pyogenes, 273
Erythrocytes, *B. divergens* in, 12
Escherichia coli
antigens, and serotyping, 295
in bacteraemia, 295
effects of ofloxacin isomer DR-3355, 227
monoclonal antibodies, 219
in urinary tract infections, 295
verotoxins, 219
Esterase activity
L. ivanovii, 111, 119
L. monocytogenes, 111, 119
Eubacteria, DNA fingerprinting, 93

Fimbriae
of *P. penneri*, 279
of salmonellae (serotype Sendai), 59
Fluid secretion in ileal loops
effects of *S. typhimurium*, 149
Fluorogenic substrate utilisation tests, 253

Gene probes, 51, 89
RNA, 91
Genital tract infection
detection of *Mobiluncus* spp., 129
effects of oestradiol, 233
by *M. hominis*, 233
mouse model for *N. gonorrhoeae*, 33
Gentamicin resistance, and *S. aureus*, 51
Giardia lamblia
antigens, 207
diagnosis, 10
in immunocompromised patients, 10
serum antibodies in giardiasis, 207
Gonococcus *see Neisseria gonorrhoeae*
Gonorrhoea, mouse model of infection, 33

Haemagglutinating activity
fimbrial, of salmonellae, 59
of *P. aeruginosa*, 285
of *P. penneri*, 279
toxin A, of *C. difficile*, 69
Haemolysins
L. ivanovii, 111, 119
L. monocytogenes, 111, 119
S. aureus, 245
Haemophilus influenzae, DNA fingerprinting, 95
Hybridisation of DNA
fingerprinting techniques, 89
molecular characterisation of *S. aureus*, 51
Southern blot, 90

Ileal loops
effects of *S. typhimurium*, 149
leucocyte influx, 149

Immunisation
against *Brucella* spp., 37, 143
mice, against *E. coli* verotoxins, 219
Immunoblotting
antigenic cross-reactivity of *Neisseria* spp., 23
Mobiluncus spp., 129
Immunocompromised patients
protozoan infections in, 3
Immunoelectronmicroscopy, 129, 279
Immunofluorescence microscopy
antibodies against *Mobiluncus* spp., 129
S. typhimurium in ileal loop model, 149
Immunoglobulins
against *Cryptosporidium* spp., 8
against verotoxins of *E. coli*, 219
anti-toxoplasma, 7
in *G. lamblia* infection, 11
Immunogold staining, 129
Immunosuppression by cyclosporin A in systemic candidiasis, 183
Inhibition tests, *Mycobacterium* spp., 175
Interferon
effect on polymorphonuclear leucocytes, 183
Iron, role in *C. jejuni* colonisation, 199
Isospora belli infections, 11

β-Lactamase, *N. gonorrhoeae*, 239
Latex agglutination immunoassay, 37
agglutination inhibition, 37
Lectins, of *P. aeruginosa*, 285
Leishmania donovani infections, 11
Leucocyte(s)
elastase, human, 285
influx, in ileal loop model, 149
radio-labelled, 149
see also Polymorphonuclear leucocytes
Lipase activity
L. ivanovii, 111, 119
L. monocytogenes, 111, 119
Lipopolysaccharides (LPS)
Brucella spp., and vaccines, 37
P. cepacia, toxicity of, 17
Liposomes
amphotericin B, 193
with antibody to *C. albicans*, 193
Listeria
L. ivanovii, extracellular enzymes, 111, 119
L. ivanovii, haemolysins, 111, 119
L. ivanovii, lipolytic activity, 111
L. monocytogenes, extracellular enzymes, 111, 119
L. monocytogenes, haemolysins, 111, 119
L. monocytogenes, lipolytic activity, 111
T-Lymphocytes
effects on polymorphonuclear leucocytes, 183

Macrophages
intracellular destruction of *S. typhimurium*, 79
Mannose resistance, of *Salmonella* spp., 59
Methicillin resistance of *S. aureus*, 51, 245
Microsporidia infections, 3, 8
Mobiluncus spp., monoclonal antibodies, 129
Monoclonal antibodies
against A and M antigens of *Brucella*, 37
against *Mobiluncus* spp., 129
against verotoxins of *E. coli*, 219
Mouse models
of bladder infection, 105
colonisation by *C. jejuni*, 199
genital infection by *M. hominis*, 233
induction of diabetes, 105
resistance to infection by *N. gonorrhoeae*, 33
systemic *C. albicans* infection, 183, 193
Mutagenesis, chemical, 143
Mycobacterium spp.
"atypical", 175
DNA fingerprinting, 96
immunoabsorbent-purified antigen, 101
radiometric studies, 175
selective inhibition tests, 175
serodiagnosis of tuberculosis, 101
Mycoplasmas
DNA fingerprinting, 92
M. hominis, effects of oestradiol on colonisation, 233
M. hominis, genital tract infection, 233
plasmids, 92

Neisseria
N. gonorrhoeae, auxotyping, 239
N. gonorrhoeae penicillinase-producing, 239
N. gonorrhoeae, plasmid profiles, 239
N. gonorrhoeae, resistance to infection, 33
N. gonorrhoeae, serotyping, 239
N. lactamica, antigenic cross-reactivity, 2
N. meningitidis, antigenic cross-reactivity, 23
N. meningitidis, vaccines, 23
N. polysaccharea, antigenic cross-reactivity, 23
ρ-Nitro-α-acetylamino-β-hydroxypropio-phenone (NAP) test, 175
ρ-Nitrobenzoic acid (PNB) test, 175
Nosocomial infections, *S. aureus*, 51, 245
Novobiocin resistance, of *S. saprophyticus*, 253

Oestradiol, and genital tract infection, 233
Ofloxacin, isomer DR-3355
bactericidal properties, 227
Oocysts
Cryptosporidium spp., 8
Isospora belli, 11
Oral streptococci
effect of penicillin on tolerant strains, 267
Organ cultures, mouse genital tract, 33

PAGE (polyacrylamide gel electrophoresis)
extracellular enzymes of *Listeria* spp., 119
fimbrial antigens of *Salmonella* spp., 59
haemolysins of *Listeria* spp., 119
toxin A of *C. difficile*, 69
two-dimensional, 69
see also SDS-PAGE

Penicillin
and tolerant oral streptococci, 267
Penicillinase-producing *N. gonorrhoeae*, 239
Peritonitis, 161, 167
Phage typing
coagulase-negative staphylococci, 161
E. coli, 295
V. cholerae, 137
vibriophage, 137
Phagocytosis
C. albicans, by polymorphonuclear leucocytes, 183
intracellular destruction of *S. typhimurium*, 79
S. aureus, by polymorphonuclear leucocytes, 245
Phosphatase activity
L. ivanovii, 111, 119
L. monocytogenes, 111, 119
Plasma membrane protein antigen
G. lamblia, 207
Plasmids
coagulase-negative staphylococci, 161
gentamicin resistance in *S. aureus*, 51
methicillin-resistance in *S. aureus*, 51
molecular characterisation of *S. aureus*, 51
and mycoplasma gene probes, 92
penicillinase-producing *N. gonorrhoeae*, 239
Pneumocystis carinii infection
diagnosis, 5
in immunocompromised patients, 3, 4
Pneumonitis, *P. carinii*, 4
Polymorphonuclear leucocytes (PMNLs)
in cystic fibrosis, 285
effects of cyclosporin A, 183
intracellular destruction of *S. typhimurium*, 79
phagocytosis of *S. aureus*, 245
role in systemic candidiasis, 183
Post-antibiotic effect (PAE), 267
PROCEEDINGS OF THE PATHOLOGICAL SOCIETY OF GREAT BRITAIN AND IRELAND Vol. 30 No. 2 October 1989. pp i–xvi
Proteeae, haemagglutinins and fimbriae, 279
Proteus penneri
fimbriae, 279
haemagglutinins, 279
Protozoan infections
diagnosis, 3
in immunocompromised patients, 3
see also Specific organisms
Providencia spp., DNA fingerprinting, 93
Pseudomonas
P. aeruginosa, adherence, 285
P. aeruginosa, DNA fingerprinting, 93
P. aeruginosa, haemagglutinins, 285
P. aeruginosa, lectins, 285
P. cepacia, DNA fingerprinting, 93
P. cepacia, extracellular toxic complex, 17
P. cepacia, virulence, 17
Pyrolysis-mass spectrometry
typing of *S. pyogenes*, 273

4-Quinolones
ofloxacin, isomer DR-3355, 227

Radiolabelling
leucocytes, 149
P. aeruginosa, 285
Radiometric selective inhibition tests, 175
Restriction endonuclease analysis
resistance plasmids of *S. aureus*, 51
techniques and applications, 89
Restriction fragment-length polymorphism, 8
RNA gene probes, 91

Salmonellae
adherence to HEp-2-cells, 59
DNA fingerprinting, 96
fimbriae, 59
mannose-resistant and eluting haemagglutinin, 59
serotype Sendai, 59
S. typhimurium, cholera toxin-related-antigen, 213
S. typhimurium infection, and leucocyte influx, 149
S. typhimurium, intracellular destruction, 79
S. typhimurium, virulence factors, 149, 213
Salt-aggregation test, 59
SDS-PAGE
toxin A of *C. difficile*, 69
whole cell proteins of *Mobiluncus* spp., 129
Serology, diagnosis of tuberculosis, 101
Serotyping
antigens of *E. coli*, 295
penicillinase-producing *N. gonorrhoeae*, 239
V. cholerae, 137
Serratia marcescens
bladder infection in diabetic mice, 105
virulence factors, 105
Serum
antigenic cross-reactivity of *Neisseria* spp., 23
Slime production
coagulase-negative staphylococci, 167
Southern blot hybridisation, 90
Spores, of microsporidia, 9
Sputum specimens, *P. carinii* in, 5
Staphylococci
coagulase-negative, 161, 167, 253
epidemiology, in CAPD peritonitis, 161, 167
novobiocin resistance, 253
S. aureus, coagulase production, 245
S. aureus, and daptomycin, 45
S. aureus, enterotoxins, 245
S. aureus, haemolysins, 245
S. aureus, gentamicin resistance, 51
S. aureus, methicillin resistance, 51, 245
S. aureus, molecular characterisation, 51
S. aureus, and ofloxacin isomer DR-3355, 227
S. aureus, plasmids, 51
S. aureus, virulence factors, 245
S. epidermidis, and ofloxacin isomer DR-3355, 227
S. saprophyticus, identification scheme, 253
S. saprophyticus, novobiocin resistance, 253
typing scheme, 161, 167
in urinary tract infections, 253

Streptococci
adherence, 267
oral, post-antibiotic effect of penicillin, 267
S. pyogenes, epidemiological typing, 273
S. pyogenes, pyrolysis-mass spectrometry, 273
S. sanguis, post-antibiotic effect of penicillin, 267

Thiophene-2-carboxylic acid hydrazide (TCH) test, 175
Thyroglobulin, bovine
affinity chromatography, 69
Toxins
extracellular toxic complex of *P. cepacia*, 17
toxin A, of *C. difficile*, 69
verotoxins of *E. coli*, 219
see also Endotoxins; Enterotoxins
Toxoplasma gondii infections, 6
diagnosis, 7
in immunocompromised patients, 5
Transferrin, and colonisation by *C. jejuni*, 199
Trophozoites
Acanthamoeba spp., 10
Cryptosporidium spp., 8
G. lamblia, 10, 207
I. belli, 11
P. carinii, 4

Tuberculosis, serodiagnosis of, 101
Turbidimetric studies, 45

Urea, anti-bacterial properties, 105
Urinary tract infections
in diabetes, 105
E. cloacae, 105
identification of *S. saprophyticus*, 253
serotyping of *E. coli*, 295
S. marcescens, 105

Vaccines
against *Brucella* spp., 37, 143
against *N. meningitidis*, 23
Verotoxins, 219
Vibrio cholerae, effects of vibriophage, 137
Vibriophage, 137
Virulence factors
Brucella spp., 143
E. cloacae, 105
P. cepacia, 17
S. aureus, 245
S. marcescens, 105
S. typhimurium, 149, 213

Western blot analysis, 219

INDEX OF AUTHORS FOR VOLUME 30

AMYES S G B, *see* LEWIN AND AMYES, 227

BARCLAY R, THRELFALL D R, LEIGHTON I. Haemolysins and extracellular enzymes of *Listeria monocytogenes* and *L. ivanovii*, 111
BARCLAY R, THRELFALL D R, LEIGHTON I. Separation and properties of the haemolysins and extracellular enzymes of *Listeria monocytogenes* and *L. ivanovii*, 119
BAYSTON R, *see* LUDLAM *et al.*, 167
BECK G, *see* PLOTKOWSKI *et al.*, 285
BERNARDO-FILHO M, *see* PLOTKOWSKI *et al.*, 285
BIGELOW N, NG L-K, ROBSON H G, DILLON J R. Strategies for molecular characterisation of methicillin- and gentamicin-resistant *Staphylococcus aureus* in a Canadian nosocomial outbreak, 51
BISTONI F, *see* VECCHIARELLI *et al.*, 183
BORRIELLO S P, *see* KAMIYA *et al.*, 69
BOSSERAY N, *see* LIMET *et al.*, 37
BURNETT I A, *see* MAGEE *et al.*, 273

CANDY D C A, *see* WALLIS *et al.*, 149
CANN KATHRYN J, ROGERS T R. Detection of antibodies to common antigens of pathogenic and commensal *Neisseria* species, 23
CARLEY AMANDA J, *see* HOLBROOK *et al.*, 267
CENCI E, *see* VECCHIARELLI *et al.*, 183
CHAMNANVANAKIT C, *see* THONGKRAJAI *et al.*, 10
CLARK J, *see* ISON *et al.*, 129
CLARKE G J, *see* QI *et al.*, 213
CLARKE G J, *see* WALLIS *et al.*, 149
COLLINS T, LEVETT P N. Radiometric studies on the use of selective inhibitors in the identification of *Mycobacterium* spp., 175

DERMOTT E, *see* ISON *et al.*, 129
DEVINE DEIDRE A, ROBINSON LENA, ROBERTS A P. Occurrence of K1, K5 and O-antigens in *Escherichia coli* isolates from patients with urinary tract infection or bacteraemia, 295
DILLON J R, *see* BIGELOW *et al.*, 51
DOYLE M P, *see* PADHYE *et al.*, 219
DUBRAY G, *see* LIMET *et al.*, 37
DUCKWORTH GEORGIA J, *see* JORDENS *et al.*, 245

EASMON C S F, *see* ISON AND EASMON, 239
EASMON C S F, *see* ISON *et al.*, 129
ELLIOTT T S J, *see* MCTAGGART AND ELLIOTT, 253

FURR P M, HETHERINGTON C M, TAYLOR-ROBINSON D. The susceptibility of germ-free, oestradiol-treated, mice to *Mycoplasma hominis*, 233

GARIN-BASTUJI B, *see* LIMET *et al.*, 37
GARNER C W, *see* STRAUS *et al.*, 17
GIRDWOOD R W A. "Protozoan" infections in the immunocompromised patient—the parasites and their diagnosis, 3
GREENWOOD D, *see* WALE *et al.*, 45
GRETZINGER K, *see* HOSPENTHAL *et al.*, 193
GUNNARSDÓTTIR STEINUNN, *see* HOLBROOK *et al.*, 267

HÄNNINEN MARJA-LIISA. Effect of endotoxin on colonisation of *Campylobacter jejuni* in infant mice, 199
HASI, *see* ZHAO *et al.*, 143
HAWKER R J H, *see* WALLIS *et al.*, 149
HETHERINGTON C M, *see* FURR *et al.*, 233
HINDMARCH J M, *see* MAGEE *et al.*, 273
HOLBROOK W P, KRISTINSSON K G, CARLEY AMANDA J, GUNNARSDÓTTIR STEINUNN. Cultural and electronmicroscopic studies of the effect of penicillin on tolerant oral streptococci, 267
HOSPENTHAL D, GRETZINGER K, ROGERS A. Treatment of a murine model of systemic candidiasis with liposomal amphotericin B bearing antibody to *Candida albicans*, 193
HSU H S, *see* LIN *et al.*, 79

ISON C A, EASMON C S F. Changes in penicillinase-producing *Neisseria gonorrhoeae* isolated in London, 239
ISON C A, KOLATOR B, REID J H, DERMOTT E, CLARK J, EASMON C S F. Characterisation of monoclonal antibodies for detection of *Mobiluncus* spp. in genital specimens, 129

JOHNSON A P, TUFFREY M, TAYLOR-ROBINSON D. Resistance of mice to genital infection with *Neisseria gonorrhoeae*, 33
JORDENS J ZOE, DUCKWORTH GEORGIA J, WILLIAMS ROSAMUND J. Production of "virulence factors" by "epidemic" methicillin-resistant *Staphylococcus aureus in vitro*, 245

KAMIYA S, REED P J, BORRIELLO S P. Purification and characterisation of *Clostridium difficile* toxin A by bovine thyroglobulin affinity chromatography and dissociation in denaturing conditions with or without reduction, 69
KHANNA R, *see* VINAYAK *et al.*, 207
KOLATOR B, *see* ISON *et al.*, 129
KRISTINSSON K G, *see* HOLBROOK *et al.*, 267
KUMKUM, *see* VINAYAK *et al.*, 207

LEIGHTON I, *see* BARCLAY *et al.*, 111, 119
LEVETT P N, *see* COLLINS AND LEVETT, 175
LEWIN C S, AMYES S G B. The bactericidal activity of DR-3355, an optically active isomer of ofloxacin, 227
LIMET J N, BOSSERAY N, GARIN-BASTUJI B, DUBRAY G, PLOMMET M. Humoral immunity in mice mediated by monoclonal antibodies against the A and M antigens of *Brucella*, 37

LIN F R, HSU H S, MUMAW V R, NAKONECZNA IRENE. Intracellular destruction of salmonellae in genetically resistant mice, 79
LONON MIRIAM K, *see* STRAUS *et al.*, 17
LU S-L, *see* ZHAO *et al.*, 143
LUDLAM H A, NOBLE W C, MARPLES R R, BAYSTON R, PHILLIPS I. The epidemiology of peritonitis caused by coagulase-negative staphylococci in continuous ambulatory peritoneal dialysis, 167
LUDLAM H A, NOBLE W C, MARPLES R R, PHILLIPS I. The evaluation of a typing scheme for coagulase-negative staphylococci suitable for epidemiological studies, 161
LULITANON V, *see* THONGKRAJAI *et al.*, 101

MCTAGGART LESLEY A, ELLIOTT T S J. Is resistance to novobiocin a reliable test for confirmation of the identification of *Staphylococcus saprophyticus*? 253
MAGEE J T, HINDMARCH J M, BURNETT I A, PEASE A. Epidemiological typing of *Streptococcus pyogenes* by pyrolysis-mass spectrometry, 273
MARCONI P, *see* VECCHIARELLI *et al.*, 183
MARPLES R R, *see* LUDLAM *et al.*, 161, 167
MARQUES E A, *see* PLOTKOWSKI *et al.*, 285
MITRA S N. Mutation induced by vibriophage PS 166 infection changes biotype and phage type of *Vibrio cholerae*, 137
MUMAW V R, *see* LIN *et al.*, 79

NAKONECZNA IRENE, *see* LIN *et al.*, 79
NG L-K, *see* BIGELOW *et al.*, 51
NISHINO T, *see* OBANA AND NISHINO, 105
NOBLE W C, *see* LUDLAM *et al.*, 161, 167

OBANA Y, NISHINO T. The virulence of *Enterobacter cloacae* and *Serratia marcescens* in experimental bladder infection in diabetic mice, 105
OLD D C, YAKUBU D E, SENIOR B W. Characterisation of a fimbrial mannose-resistant and eluting haemagglutinin (MREHA) produced by strains of *Salmonella* of serotype Sendai, 59
OLD D C, *see* YAKUBU *et al.*, 279
OSBORNE M P, *see* WALLIS *et al.*, 149
OWEN R J. Chromosomal DNA fingerprinting—a new method of species and strain identification applicable to microbial pathogens, 89

PADHYE V V, ZHAO T, DOYLE M P. Production and characterisation of monoclonal antibodies to Verotoxins 1 and 2 from *Escherichia coli* of serotype O157:H7, 219
PEASE A, *see* MAGEE *et al.*, 273
PHILLIPS I, *see* LUDLAM *et al.*, 161, 167
PLOMMET M, *see* LIMET *et al.*, 37
PLOTKOWSKI M C, BECK G, TOURNIER J M, BERNARDO-FILHO M, MARQUES E A, PUCHELLE E. Adherence of *Pseudomonas aeruginosa* to respiratory epithelium and the effect of leucocyte elastase, 285
PUCHELLE, E, *see* PLOTKOWSKI *et al.*, 285

QI G-M, CLARKE G J, WALLIS T S, STEPHEN J. The influence of cultural conditions on the expression in *Salmonella typhimurium* of an antigen related to cholera toxin, 213
QI G-M, *see* WALLIS *et al.*, 149
QIN Y-X, *see* ZHAO *et al.*, 143

REED P J, *see* KAMIYA *et al.*, 69
REID J H, *see* ISON *et al.*, 129
RICCARDI C, *see* VECCHIARELLI *et al.*, 183
ROBERTS A P, *see* DEVINE *et al.*, 295
ROBINSON LENA, *see* DEVINE *et al.*, 295
ROBSON H G, *see* BIGELOW *et al.*, 51
ROGERS A, *see* HOSPENTHAL *et al.*, 193
ROGERS T R, *see* CANN AND ROGERS, 23
ROSSI R, *see* VECCHIARELLI *et al.*, 183

SENIOR B W, *see* OLD *et al.*, 59
SENIOR B W, *see* YAKUBU *et al.*, 279
SHELTON A P, *see* WALE *et al.*, 45
STEPHEN J, *see* QI *et al.*, 213
STEPHEN J, *see* WALLIS *et al.*, 149
STRAUS D C, LONON MIRIAM K, WOODS D E, GARNER C W. Production of an extracellular toxic complex by various strains of *Pseudomonas cepacia*, 17

TAYLOR-ROBINSON D, *see* FURR *et al.*, 233
TAYLOR-ROBINSON D, *see* JOHNSON *et al.*, 33
THRELFALL D R, *see* BARCLAY *et al.*, 111, 119
THONGKRAJAI P, LULITANON V, CHAMNANVANAKIT C. Improved ELISA with immunoabsorbent-purified mycobacterial antigen for serodiagnosis of tuberculosis, 101
TOURNIER J M, *see* PLOTKOWSKI *et al.*, 285
TUFFREY M, *see* JOHNSON *et al.*, 33

VECCHIARELLI A, CENCI E, MARCONI P, ROSSI R, RICCARDI C, BISTONI F. Immunosuppressive effect of cyclosporin A on resistance to systemic infection with *Candida albicans*, 183
VINAYAK V K, KUMKUM, KHANNA R. Serum antibodies to giardial surface antigens: lower titres in persistent than in nonpersistent giardiasis, 207

WALE LINDA J, SHELTON A P, GREENWOOD D. Scanning electronmicroscopy of *Staphylococcus aureus* and *Enterococcus faecalis* exposed to daptomycin, 45
WALLIS T S, HAWKER R J H, CANDY D C A, QI G-M, CLARKE G J, WORTON K J, OSBORNE M P, STEPHEN J. Quantification of the leucocyte influx into rabbit ileal loops induced by strains of *Salmonella typhimurium* of different virulence, 149
WALLIS T S, *see* QI *et al.*, 213
WENDOSO, *see* ZHAO *et al.*, 143
WENG WANG, *see* ZHAO *et al.*, 143
WILLIAMS ROSAMUND J, *see* JORDENS *et al.*, 245
WOODS D E, *see* STRAUS *et al.*, 17
WORTON K J, *see* WALLIS *et al.*, 149

YAKUBU D E, OLD D C, SENIOR B W. The haemagglutinins and fimbriae of *Proteus penneri*, 279
YAKUBU D E, *see* OLD *et al.*, 59
ZHAO T, *see* PADHYE *et al.*, 219
ZHAO W-R, WENDOSO, HASI, QIN Y-X, WENG WANG, LU S-L. Selection of a *Brucella* vaccine strain of low residual virulence by chemical mutagenesis, 143